Literature DB >> 32405253

Combination of four clinical indicators predicts the severe/critical symptom of patients infected COVID-19.

Liping Sun1, Gang Liu1, Fengxiang Song2, Nannan Shi2, Fengjun Liu2, Shenyang Li2, Ping Li1, Weihan Zhang2, Xiao Jiang3, Yongbin Zhang1, Lining Sun1, Xiong Chen2, Yuxin Shi2.   

Abstract

Background: Despite the death rate of COVID-19 is less than 3%, the fatality rate of severe/critical cases is high, according to World Health Organization (WHO). Thus, screening the severe/critical cases before symptom occurs effectively saves medical resources. Methods and materials: In this study, all 336 cases of patients infected COVID-19 in Shanghai to March 12th, were retrospectively enrolled, and divided in to training and test datasets. In addition, 220 clinical and laboratory observations/records were also collected. Clinical indicators were associated with severe/critical symptoms were identified and a model for severe/critical symptom prediction was developed.
Results: Totally, 36 clinical indicators significantly associated with severe/critical symptom were identified. The clinical indicators are mainly thyroxine, immune related cells and products. Support Vector Machine (SVM) and optimized combination of age, GSH, CD3 ratio and total protein has a good performance in discriminating the mild and severe/critical cases. The area under receiving operating curve (AUROC) reached 0.9996 and 0.9757 in the training and testing dataset, respectively. When the using cut-off value as 0.0667, the recall rate was 93.33% and 100% in the training and testing datasets, separately. Cox multivariate regression and survival analyses revealed that the model significantly discriminated the severe/critical cases and used the information of the selected clinical indicators.
Conclusion: The model was robust and effective in predicting the severe/critical COVID cases.
© 2020 Published by Elsevier B.V.

Keywords:  COVID-19; SVM; critical/severe symptom; prediction

Year:  2020        PMID: 32405253      PMCID: PMC7219384          DOI: 10.1016/j.jcv.2020.104431

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  5 in total

1.  Bats are natural reservoirs of SARS-like coronaviruses.

Authors:  Wendong Li; Zhengli Shi; Meng Yu; Wuze Ren; Craig Smith; Jonathan H Epstein; Hanzhong Wang; Gary Crameri; Zhihong Hu; Huajun Zhang; Jianhong Zhang; Jennifer McEachern; Hume Field; Peter Daszak; Bryan T Eaton; Shuyi Zhang; Lin-Fa Wang
Journal:  Science       Date:  2005-09-29       Impact factor: 47.728

2.  Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future.

Authors:  Chris T Bauch; James O Lloyd-Smith; Megan P Coffee; Alison P Galvani
Journal:  Epidemiology       Date:  2005-11       Impact factor: 4.822

3.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

4.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

5.  Pathology of the thyroid in severe acute respiratory syndrome.

Authors:  Lan Wei; Shen Sun; Cai-Hong Xu; Jing Zhang; Yun Xu; Hong Zhu; Suat-Cheng Peh; Christine Korteweg; Michael A McNutt; Jiang Gu
Journal:  Hum Pathol       Date:  2006-09-25       Impact factor: 3.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.